Enzymatica AB

Equities

ENZY

SE0003943620

Pharmaceuticals

Market Closed - Nasdaq Stockholm 11:29:33 2024-04-29 am EDT 5-day change 1st Jan Change
2.91 SEK -5.52% Intraday chart for Enzymatica AB -15.65% -26.24%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Enzymatica AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Enzymatica AB Announces Composition of Nomination Committee CI
Enzymatica Obtains CE Marking for ColdZyme Mouth Spray MT
Enzymatica AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Enzymatica AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Enzymatica’s Oral Spray Trial Reduces Viral Load in Common Colds MT
Enzymatica AB Announces Interim Report from Clinical Study: ColdZyme Significantly Reduces Rhinovirus Viral Load and Symptoms of Sore Throat CI
Enzymatica AB Announces New Study CI
Enzymatica AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Enzymatica AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Enzymatica AB Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Enzymatica AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Enzymatica AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Enzymatica Surges 35% After New Study Confirms ColdZyme Stops Omicron From Infecting Human Cells MT
Enzymatica AB(OM:ENZY) dropped from S&P Global BMI Index CI
Enzymatica Raises $7 Million Via Rights Issue MT
Enzymatica To Boost Financial Position Via $7 Million Rights Offering MT
Enzymatica AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Enzymatica AB Announces New Data from an Ongoing In-Vitro Study CI
Enzymatica AB Appoints Moa Fransson as New Member of the Board CI
Enzymatica AB Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Enzymatica Rises 7% Ahead Of Mouth Spray Launch In Turkey MT
Enzymatica AB Announces Mouth Spray Product Will Be Marketed, Sold, and Distributed in Turkey by Sanofi Consumer Health Care CI
Enzymatica AB's Mouth Spray to Be Launches in Turkey CI
Enzymatica and Sanofi Launches Mouth Spray in Mexico CI
Chart Enzymatica AB
More charts
Enzymatica publ AB is a Sweden-based company engaged in biotechnology. It researches, develops and registers enzyme-based health and wellbeing products. The Company uses a patented enzyme, Penzyme, a cold-adapted trypsin from deep sea cod. The enzyme is active at about 37 Celsius degree and decomposes disease-related proteins, counteracting viral and bacterial infections and supporting healing processes. The Company conducts clinical studies of ColdZyme Munspray, a cold medicine. It operates such subsidiaries, as Enzymatica Care AB, Zymetech ehf, among others. Main shareholders of Enzymatica AB are Humea AB, Medi AB, and Nordic Consulting Group AB, among others. In November 2013, the Company established another subsidiary in the United States, Enzymatica North America Inc., responsible for future production and sale of veterinary products in the United States and Canada.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. ENZY Stock
  4. News Enzymatica AB
  5. Enzymatica Surges 35% After New Study Confirms ColdZyme Stops Omicron From Infecting Human Cells